Physician profile
Eric P Robinson
NPI 1225041718
$3,266.21
in general payments reported to CMS, 2019-2025
20 companies · $316 in 2025
The $316 reported for 2025 was less than what a typical Interventional Pain Medicine provider received nationally (typical 2025 total: $676).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,245 · 2020: $305 · 2021: $283 · 2022: $328 · 2023: $338 · 2024: $451 · 2025: $316.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,104.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,826.76 | 2019-2025 | Proclaim, Eterna, Prodigy |
| Scilex Pharmaceuticals INC. | $378.95 | 2019-2025 | Ztlido |
| Collegium Pharmaceutical, INC. | $364.66 | 2021-2025 | Belbuca, Xtampza |
| Boston Scientific Corporation | $171.64 | 2020-2025 | Intracept |
| Arbor Pharmaceuticals, INC. | $128.98 | 2020-2021 | |
| Assertio Therapeutics, INC. | $51.18 | 2019-2020 | |
| Amgen INC. | $43.25 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $39.04 | 2024-2025 | |
| Lilly USA, LLC | $33.88 | 2019-2020 | |
| Abbvie INC. | $29.09 | 2024 | |
| Pfizer INC. | $27.39 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $24.41 | 2019 | |
| Almatica Pharma LLC | $20.54 | 2021 | |
| Si-Bone, INC. | $20.05 | 2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $19.45 | 2019 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company Ltd. | $19.11 | 2022 | |
| Ibsa Pharma INC. | $18.81 | 2022 | |
| Bioventus LLC | $17.08 | 2019 | |
| Biodelivery Sciences International, INC. | $16.66 | 2021 | |
| Averitas Pharma INC. | $15.28 | 2024 | Qutenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Eric Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.